Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $7.6 million.

  • Xeris Biopharma Holdings' Share-based Compensation rose 1292.85% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.7 million, marking a year-over-year increase of 1798.69%. This contributed to the annual value of $18.4 million for FY2024, which is 7136.06% up from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Share-based Compensation stood at $7.6 million for Q3 2025, which was up 1292.85% from $5.0 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' Share-based Compensation's 5-year high stood at $7.6 million during Q3 2025, with a 5-year trough of $2.5 million in Q3 2023.
  • Over the past 5 years, Xeris Biopharma Holdings' median Share-based Compensation value was $3.2 million (recorded in 2022), while the average stood at $3.7 million.
  • In the last 5 years, Xeris Biopharma Holdings' Share-based Compensation tumbled by 2232.66% in 2023 and then skyrocketed by 17545.79% in 2024.
  • Xeris Biopharma Holdings' Share-based Compensation (Quarter) stood at $2.7 million in 2021, then grew by 0.84% to $2.8 million in 2022, then rose by 0.04% to $2.8 million in 2023, then increased by 29.92% to $3.6 million in 2024, then skyrocketed by 112.6% to $7.6 million in 2025.
  • Its last three reported values are $7.6 million in Q3 2025, $5.0 million for Q2 2025, and $4.4 million during Q1 2025.